RxDoctor Payments Data

Andrew Rosenzweig, MD

Geriatric Psychiatry · Providence, RINPI 1942203690

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $240,311 of the $313,687 with a category attached, or 76.6%. 4 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 41.4% of the total.

$313,687in general payments, 2019–2025

Across 482 payments — averaging $650.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$130K
  • Otsuka America Pharmaceutical, Inc.$127K
  • Neurocrine Biosciences, Inc.$56K
  • Teva Pharmaceuticals USA, Inc.$197
$1,000in research payments, 2019–2025

Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$1K

What the payments were for

  • Consulting fees$31,15010%
  • Speaking & faculty fees$240,31177%
  • Travel & lodging$29,6769%
  • Food & beverage$12,5514%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric psychiatry providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$11,474
Medicare patients
84
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl12$204

Paid to pharmacies, not to this prescriber.

Other geriatric psychiatry in Providence

Where these figures come from

Is this you, or does something look wrong? →